- Home
- LDTC vs ICU Comparison
LDTC vs ICU Comparison
Compare LDTC & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- ICU
- Stock Information
- Founded
- LDTC 2007
- ICU 2018
- Country
- LDTC Canada
- ICU United States
- Employees
- LDTC N/A
- ICU N/A
- Industry
- LDTC Blank Checks
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- ICU Health Care
- Exchange
- LDTC Nasdaq
- ICU Nasdaq
- Market Cap
- LDTC 10.6M
- ICU 10.3M
- IPO Year
- LDTC N/A
- ICU N/A
- Fundamental
- Price
- LDTC $1.01
- ICU $2.00
- Analyst Decision
- LDTC Buy
- ICU
- Analyst Count
- LDTC 3
- ICU 0
- Target Price
- LDTC $3.00
- ICU N/A
- AVG Volume (30 Days)
- LDTC 21.8M
- ICU 24.8K
- Earning Date
- LDTC 12-18-2024
- ICU 11-13-2024
- Dividend Yield
- LDTC N/A
- ICU N/A
- EPS Growth
- LDTC N/A
- ICU N/A
- EPS
- LDTC N/A
- ICU N/A
- Revenue
- LDTC $353,686.00
- ICU $68,000.00
- Revenue This Year
- LDTC N/A
- ICU N/A
- Revenue Next Year
- LDTC $9.55
- ICU $344.44
- P/E Ratio
- LDTC N/A
- ICU N/A
- Revenue Growth
- LDTC 141.86
- ICU N/A
- 52 Week Low
- LDTC $0.22
- ICU $1.70
- 52 Week High
- LDTC $9.99
- ICU $42.93
- Technical
- Relative Strength Index (RSI)
- LDTC 53.75
- ICU 39.05
- Support Level
- LDTC $1.05
- ICU $1.70
- Resistance Level
- LDTC $2.05
- ICU $2.04
- Average True Range (ATR)
- LDTC 0.34
- ICU 0.19
- MACD
- LDTC 0.06
- ICU 0.01
- Stochastic Oscillator
- LDTC 30.12
- ICU 33.33
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.